| DB ID | MyCo_3922 |
| Title | Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis |
| Year | 2016 |
| PMID | 26931315 |
| Fungal Diseases involved | Pulmonary mucormycosis |
| Associated Medical Condition | Neutropenic leukaemia |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The local institutional review board of University Hospital of Dijon, France has approved the study. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | PCT |
| Biomarker Full Name | Procalcitonin |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | Between January 2009 and May 2015, we retrospec-tively studied patients who had received intensive chemotherapies (inducing prolonged and deep neu- tropenia defined as a white blood cells (WBC) count below 500 mm 3) with curative intent for acute myeloblastic (AML) or lymphoblastic leukaemia (ALL) at the Department of Clinical Haematology, University Hospital of Dijon, France. Total 94 leukaemia patients with proven/probable IPA (n = 77) or PM (n = 17) were included. |
| Cohort No. | 94 |
| Age Group | 23–83 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal infections (IFI), especially invasive pulmonary aspergillosis (IPA) and mucormycosis (PM), are a major cause of morbidity and mortality in haematological malignancies. The prevalence ranges from 2% to 40%, depending on the disease and treat- ment administered. Mortality rates can reach 40% to 60%. The incidence of IPA or PM has increased during the last two decades especially following pro- longed neutropenia induced by intensive cytotoxic chemotherapies. |
| Technique | Immunological assay |
| Analysis Method | Immunofluorescence analysis |
| ELISA kits | Fib test kit (Platelia Aspergillusâ, Bio-Rad, Marnes la Coquette, France) |
| Assay Data | None |
| Validation Techniques used | Immunofluorescence analysis, Nephelometry, Fib testing |
| Up Regulation Down Regulation | Decrease |
| Sequence Data | None |
| External Link | None |
